Skip to main content
News

Arancisa’s Houda Hachad Guest MedCity Influencer in MedCity News

By April 20, 2025December 24th, 2025No Comments

Houda Hachad, PharmD, M.Res, discusses PGx testing for DPYD prior to common chemotherapy treatments to avoid toxicities due to genetic variants.

“In the United States, approximately 275,000 cancer patients receive fluorouracil annually, and it is estimated that 3% develop some degree of toxic reaction. Each year, 1,300 patients experience fatal toxicity. Identifying patients who carry harmful DPYD gene variants through PGx testing before chemotherapy administration is critical for preventing these severe toxicities.” – Houda Hachad, PharmD, M.Res


Click here to read more about DPYD testing for safer cancer treatment in MedCity News.

Leave a Reply